Contrary To Misinformation, COVID-19 Mortality And Hospitalization Has Been Rising In The Last 30 Days Globally. Please Take Precautions!

Source: Thailand Medical News  Dec 29, 2019  3 years ago
Israel's Icecure Gets US FDA To Expand To Treat Tumours In Liver, Kidney Besides Breast Tumors
Israel's Icecure Gets US FDA To Expand To Treat Tumours In Liver, Kidney Besides Breast Tumors
Source: Thailand Medical News  Dec 29, 2019  3 years ago
IceCure Medical, an Israel based company said that it received US regulatory approval to expand the use of its cryoablation technology to treat benign and cancerous tumors in livers and kidneys.

The IceCure's treatment platform uses special needles to inject liquid nitrogen to freeze and destroy tumors without the need for surgery.

IceCure had initially focused on breast tumors, but now the US Food and Drug Administration (FDA) approved new uses, such as against tumors in the kidney, liver and in the fields of neurology and ear, nose and throat, the company said.

The FDA also approved its new MultySense system that has three probes, it said. Its earlier system had one needle.

IceCure Chief Executive Eyal Shamir told Thailand Medical news via a phone interview, "This machine will allow us to treat bigger tumors or a few different tumors at the same time of treatment. Also we have a  new system that is slated to be launched at the end of 2020.”

IceCure Medical develops and markets minimally invasive cryoablation therapies for women's health and the general oncology market. The company's proprietary IceSense3 and ProSense systems provide minimally invasive, in-office definitive treatment for symptomatic tumors in various organs.

The minimally invasive cryoablation procedure is done under ultrasound or CT imaging to guide a small probe (thin hollow needle) into the tumor. The system then uses extremely cold temperatures to ablate the targeted tumor in situ. The cryoablation procedure is a safe and effective treatment option that can be performed quickly in a doctor's office.

IceCure has US FDA and CE approval for broad benign and malignant indications. The company's ProSense is available in the United States, Europe, Hong Kong, Thailand, Singapore, Central America, and South America. The company is also undergoing the regulatory process in China with the CFDA as well as other Asian and South American countries.

It is currently participating in several clinical studies for the treatment of lung, kidney, and breast cancer (under clinical studies in the United States and Japan).


Sep 25, 2022  4 months ago
Source: Medical News - SARS-CoV-2 Fall And Winter 2022 Variant Collections
Sep 08, 2022  5 months ago
Source- Medical News - COVID-19 Research - Impaired Pain Modulation
Aug 04, 2022  6 months ago
Source: Medical News - SARS-CoV-2 & Cancer
Aug 13, 2020  3 years ago
Source: Supplements For COVID-19
Feb 05, 2020  3 years ago
Source : Thailand Medical news